Cancer clinical trials in the region Nouvelle-Aquitaine

264 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account
and find trials relevant to your profile

Phase 2 Endometrial cancer #NCT05489211 #2023-509436-26-00

[TROPION-PanTumor03] Étude du DATO-DXD en monothérapie et en association avec des agents anticancéreux chez des patients atteints de tumeurs solides avancées

Locally Advanced Metastatic 1 2 3 or more

Antibody Drug Conjugates (ADC) Systemic Treatment-Naive Antibody Drug Conjugates (ADC)

Institut Bergonié (Bordeaux)

AstraZeneca

Phase 2 Lymphoma #NCT04802590 #2024-512634-15-00

Étude sur l'IBRUTINIB + un anticorps anti-CD20 et le VENETOCLAX chez des patients atteints de lymphome à cellules du manteau non traité

B cell lymphoma Mantel cell lymphoma None CD20 > 60 ml/min 50-60 ml/min None Systemic Treatment-Naive

Centre Hospitalier Universitaire Dupuytren (Limoges), CHU - Haut-Lévêque - Bordeaux (Pessac), Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers), Centre Hospitalier de la Côte Basque (Bayonne)

The Lymphoma Academic Research Organisation (LYSARC)

Phase 2 Lung cancer #NCT06868485 #2024-519713-65-00

Étude visant à évaluer l'efficacité du WSD0922-FU chez les patients atteints d'un cancer du poumon non à petites cellules avancé C797S +

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR 1 Targeted therapy

Systemic Treatment-Naive

Centre Hospitalier Universitaire Dupuytren (Limoges), CHU - Haut-Lévêque - Bordeaux (Pessac)

Wayshine Biopharm, Inc.

Phase 2 Pancreas cancer #NCT06172478 #2023-507641-29-00

[HERTHENA-PanTumor01] Etude sur HER3-DXd chez des sujets atteints de tumeurs solides localement avancées ou métastatiques

Adenocarcinoma Locally Advanced Metastatic 1

Systemic Treatment-Naive

Groupe Hospitalier Saint André (Bordeaux)

Daiichi Sankyo

Phase 2 Breast cancer #NCT05215106 #2024-512082-14-00

[POP-DURVA] Étude du DURVALUMAB (MEDI 4736) préopératoire de courte durée chez des patientes atteintes d'un cancer du sein triple négatif de petite taille

HER2 Negative HR Negative Localized None Systemic Treatment-Naive

Surgery Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC) Radiotherapy

Institut Bergonié (Bordeaux)

Gustave Roussy, Campus du cancer, Grand Paris

Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer #NCT06760819 #2024-517419-62-00

[panSOHO] Etude sur l'efficacité du BAY2927088 et sur son innocuité chez les participants atteints d'une tumeur solide présentant des mutations activatices d'HER2

Stomach Oesogastric junction Esophagus Adenocarcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Ampullary carcinoma Gastrointestinal stromal tumor Squamous cell carcinoma Other HER2 Positive Locally Advanced Metastatic Metastatic Castration-resistant HER2 1

Systemic Treatment-Naive

Institut Bergonié (Bordeaux)

Bayer

Phase 2 Stomach and esophageal cancer #NCT05489211 #2023-509436-26-00

[TROPION-PanTumor03] Étude du DATO-DXD en monothérapie et en association avec des agents anticancéreux chez des patients atteints de tumeurs solides avancées

Stomach Locally Advanced Metastatic 1 2 3 or more

Antibody Drug Conjugates (ADC) Systemic Treatment-Naive Antibody Drug Conjugates (ADC)

Institut Bergonié (Bordeaux)

AstraZeneca

Phase 2 Breast cancer #NCT06172478 #2023-507641-29-00

[HERTHENA-PanTumor01] Etude sur HER3-DXd chez des sujets atteints de tumeurs solides localement avancées ou métastatiques

HER2 Negative HR Positive Locally Advanced Metastatic 1 Chemotherapy Targeted therapy Hormone therapy

ALK BRAF EGFR HER2 KRAS G12C MET NTRK-1/2/3 RET ROS-1 Systemic Treatment-Naive

Groupe Hospitalier Saint André (Bordeaux)

Daiichi Sankyo

Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05503797 #2024-513578-23-00

Etude visant à évaluer l'efficacité et la sécurité du FORE8394 chez des participants atteints d'un cancer présentant des altérations du gène BRAF - Sous protocole A

Locally Advanced Metastatic BRAF 1 2 3 or more

KRAS G12C KRAS non G12C NRAS HRAS Systemic Treatment-Naive

Institut Bergonié (Bordeaux)

Fore Biotherapeutics

Phase 2 Prostate cancer #NCT05826509 #2022-501518-67-00

[SUGAR] CHIRURGIE avec ou sans DAROLUTAMIDE dans le cancer de la prostate à haut risque et/ou localement avancé

Adenocarcinoma Localized None Systemic Treatment-Naive Systemic Treatment-Naive

Institut Bergonié (Bordeaux), Centre Hospitalier Universitaire de Bordeaux (Bordeaux)

Institut Claudius Regaud